The future of drug discovery is human.
Human iPSC-derived organoids to predict efficacy and safety before clinical trials.
Human iPSC-derived organoids to predict efficacy and safety before clinical trials.
R&D is broken: 90% of drug candidates fail, pushing the average cost of an approval to ~$2.6B.
Over half of R&D costs are lost late in development. One Phase III failure can cost $750 million.
Late-stage failures are dominated by efficacy and safety.
of failures are due to safety or efficacy.
A complete pipeline that delivers predictive drug insights through human genetic diversity.
Genetically diverse human donors representing global populations.
Reprogrammed stem cells annotated with detailed pharmacogenetic profiles.
Functional human tissues modeling real safety and efficacy responses.
Human-relevant data that reveal safety and efficacy before clinical trials.
Number of iPSC lines per tier, and % coverage of CPIC/FDA PGx liabilities.
Partner with us to redefine preclinical testing with predictive human biology.